Dosimetry of Three-Dimensional Conformal Radiotherapy (3D-CRT) Versus Volumetric Modulated Arc Therapy (VMAT) in Hypopharyngeal Cancer

Authors

  • Fatimatou Néné Sarr Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Mouhamadou Bachir Ba Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Awa Sadikh Badiane Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Rachidou Hamadou Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Moussa Diallo Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Massamba Diène Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Kanta Ka International Cancer Center of Dakar, Senegal Author
  • Maimouna Mané Radiotherapy Department, Cheikhoul Khadim Hopital, Dakar, Senegal Author
  • Mamadou Moustapha Dieng Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author
  • Papa Macoumba Gaye Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal Author

DOI:

https://doi.org/10.47363/JONRR/2025(6)191

Keywords:

Hypopharynx, Carcinoma, Radiotherapy, VMAT, 3D-CRT

Abstract

 Objectives: IMRT or VMAT is the standard for curative treatment of hypopharyngeal carcinoma. In our setting, 3D-CRT is widely used due to limited IMRT availability. This study aimed to compare dosimetry between these techniques.

Methods: A retrospective, bicentric study included 30 patients with hypopharyngeal squamous cell carcinoma (15 3D-CRT, 15 VMAT). Prescribed doses were 70 Gy/35 fractions for 3D-CRT and 64–70 Gy for VMAT. Target volumes and organs at risk were analyzed per ICRU 50 standards.

Results: PTV coverage at V95% was comparable. VMAT reduced hot spots (V107%: 0.10% vs 47.46%, p < 0.001) and improved dose homogeneity (HI: 0.08 vs 0.81, p < 0.001). VMAT also lowered spinal cord maximum dose (40.85 vs 47.40 Gy, p < 0.001) and parotid mean doses (left: 28.12 vs 38.01 Gy, right: 28.27 vs 38.57 Gy; p < 0.05).

Conclusion: In resource-limited settings, 3D-CRT ensures adequate tumor coverage. VMAT provides better dose homogeneity and spares organs at risk, potentially reducing toxicity and improving quality of life.

Author Biographies

  • Fatimatou Néné Sarr, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Mouhamadou Bachir Ba, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Awa Sadikh Badiane, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Rachidou Hamadou, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Moussa Diallo, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Massamba Diène, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Kanta Ka, International Cancer Center of Dakar, Senegal

    International Cancer Center of Dakar, Senegal

  • Maimouna Mané, Radiotherapy Department, Cheikhoul Khadim Hopital, Dakar, Senegal

    Radiotherapy Department, Cheikhoul Khadim Hopital, Dakar, Senegal

  • Mamadou Moustapha Dieng, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

  • Papa Macoumba Gaye, Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

    Radiotherapy Department, Dalal Jamm Hospital, Dakar, Senegal

Downloads

Published

2025-11-09 — Updated on 2025-12-05

Versions